Recent posts
It was finally good news for Watertown-based Acusphere (NASDAQ: ACUS) this week, as the company reported positive clinical trial results for its lead product, called Imagify, at the American Heart... Read more »
If all goes as planned, Cambridge-based RNAi pioneer Alnylam (NASDAQ: ALNY) will be celebrating Thanksgiving with a new competitor in its backyard, in the form of Dicerna Pharmaceuticals, a brand-new... Read more »
It passed the House by a vote of 420 to 3, President Bush is for it, and it has fervent supporters on both sides of the political aisle—but even that didn’t... Read more »
Genzyme (NASDAQ: GENZ) and China are probably the world’s biggest players in gene therapy, and now the two are working together, thanks to a deal announced last Friday around Genzyme’s... Read more »
A new company focused on products that harness the immune system will be formed through the merger of Needham, MA-based Avant Immunotherapeutics (NASDAQ: AVAN) and privately held, Phillipsburg, NJ-based Celldex Therapeutics.... Read more »
It’s got advisors like Bob Langer and Judah Folkman, a particularly innovative strategy, and more than 15 years of research behind it. But Lexington, MA-based Predictive Biosciences is starting out by... Read more »
In a move that will create one of the largest life sciences companies in Massachusetts, shareholders of both Hologic (NASDAQ: HOLX) and Cytyc (NASDAQ: CYTC) today approved Bedford, MA-based... Read more »
Ouch. After years of waiting for the good news that would push its test into the mainstream, Exact Sciences instead just got a warning letter from the FDA. It could... Read more »
Talk about a colorful past. Spun out of a blood-collection business shortly after 9/11, SeraCare Life Sciences saw its fortunes skyrocket and then crash spectacularly. Now, just a few months after... Read more »
Yes, that’s $1.1 billion.
GlaxoSmithKline (NYSE: GSK) leapt at STA-4783 just a couple of weeks after Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) presented some promising news about the experimental... Read more »
The market for age-related macular degeneration (AMD) treatments is expected to balloon over the next few years as the population gets older, and plenty of people think there’s room for some... Read more »
What? Can antisense possibly be hot again? Many people wondered if the decades-old RNA-targeting approach to drug development was even still alive. But look again. Recent events show antisense isn’t just... Read more »
